Checkpoint inhibition and melanoma: Considerations in treating the older adult Checkpoint inhibition and melanoma: Considerations in treating the older adult

The incidence of melanoma and associated mortality rate from advanced disease in older adults is increasing over time. Checkpoint inhibitors have demonstrated a survival benefit for the treatment of stage IV or unresectable stage III disease and have become one of the standards of care. Data suggests that adults aged 65 and older benefit from treatment with checkpoint inhibitors without an increased incidence in adverse events. However, clinicians should be aware of the potential side effects of this class of medications and how to manage them in older adults. (C) 2017 Elsevier Ltd. All rights reserved.